Prevalence of Ambler class A and D β-lactamases among clinical isolates of Pseudomonas aeruginosa in Korea

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 1, 2005, Pages 122-127

  Lee, Seungok ^a   Park, Yeon Joon ^b   Kim, Myungshin ^b   Lee, Hae Kyung ^b   Han, Kyungja ^b   Kang, Chang Suk ^b   Kang, Moon Won ^c  

^a Seoul Medical Science Institute   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

ESBLs; Extended spectrum lactamases; OXA 17; P. aeruginosa

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAMASE; BETA LACTAMASE OXA; BETA LACTAMASE OXA 10; BETA LACTAMASE OXA 17; BETA LACTAMASE PSE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLOXACILLIN; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; TIMENTIN; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; ENZYME ANALYSIS; ENZYME POLYMORPHISM; ISOELECTRIC FOCUSING; KOREA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS; STRUCTURAL GENE; CLASSIFICATION; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; MICROBIOLOGICAL EXAMINATION;

BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA;

EID: 24044487920     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki160     Document Type: Article

References (32)

1. Cavallo JD, Fabre R, Leblanc F [i#et al.#1i] Antibiotic susceptibility and mechanisms of β-lactam resistance in 1310 strains of [i#Pseudomonas aeruginosa#1i]: A French multicentre study (1996). [i#J Antimicrob Chemother#1i] 2000; [b#46#1b]: 133-6.
2. Chen HY, Yuan M, Livermore DM. Mechanisms of resistance to β-lactam antibiotics amongst [i#Pseudomonas aeruginosa#1i] isolates collected in the UK in 1993. [i#J Med Microbiol#1i] 1995; [b#43#1b]: 300-9.
3. Nordmann P, Guibert M. Extended-spectrum β-lactamases in [i#Pseudomonas aeruginosa. J Antimicrob Chemother#1i] 1998; [b#42#1b]: 128-31.
4. Weldhagen GF, Poirel L, Nordmann P. Ambler class A extended-spectrum β-lactamases in [i#Pseudomonas aeruginosa#1i]: Novel developments and clinical impact. [i#Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 2385-92.
5. Toleman MA, Rolston K, Jones RN [i#et al.#1i] Molecular and biochemical characterization of OXA-45, an extended-spectrum class 2d′ β-lactamase in [i#Pseudomonas aeruginosa. Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 2859-63.
6. Bert F, Branger C, Lambert-Zechovsky N. Identification of PSE and OXA β-lactamase genes in [i#Pseudomonas aeruginosa#1i] using PCR-restriction fragment length polymorphism. [i#J Antimicrob Chemother#1i] 2002; [b#50#1b] 11-18.
7. Lee K, Lee WG, Uh Y [i#et al.#1i] VIM- and IMP-type metallo-β-lactamase-producing [i#Pseudomonas#1i] spp. and [i#Acinetobacter#1i] spp. in Korean hospitals. [i#Emerg Infect Dis#1i] 2003; [b#9#1b]: 868-71.
8. Lee K, Ha GY, Shin BM [i#et al.#1i] Metallo-β-lactamase-producing Gram-negative bacilli in Korean Nationwide Surveillance of Antimicrobial Resistance group hospitals in 2003: Continued prevalence of VIM-producing [i#Pseudomonas#1i] spp. and increase of IMP-producing [i#Acinetobacter#1i] spp. [i#Diagn Microbiol Infect Dis#1i] 2004; [b#50#1b]: 51-8.
9. National Committee for Clinical Laboratory Standards. [i#Performance Standards for Antimicrobial Disc Susceptibility Test - Seventh Edition: Approved Standard M2-A7#1i]. Wayne, PA, USA: NCCLS, 2001.
10. De Champs C, Poirel L, Bonnet R [i#et al.#1i] Prospective survey of β-lactamases produced by ceftazidime-resistant [i#Pseudomonas aeruginosa#1i] isolated in a French hospital in 2000. [i#Antimicrob Agents Chemother#1i] 2002; [b#46#1b]: 3031-4.
11. Danel F, Hall LM, Gur D [i#et al.#1i] Transferable production of PER-1 β-lactamase in [i#Pseudomonas aeruginosa. J Antimicrob Chemother#1i] 1995; [b#35#1b]: 281-94.
12. Naas T, Benaoudia F, Massuard S [i#et al.#1i] Integron-located VEB-1 extended-spectrum β-lactamase gene in a [i#Proteus mirabilis#1i] clinical isolate from Vietnam. [i#J Antimicrob Chemother#1i] 2000; [b#46#1b] 703-11.
13. Aubert D, Poirel L, Chevalier J [i#et al.#1i] Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in [i#Pseudomonas aeruginosa. Antimicrob Agents Chemother#1i] 2001; [b#45#1b]: 1615-20.
14. Mabilat C, Goussard S. PCR detection and identification of genes for extended-spectrum β-lactamases. In: Persing DH, Smith TF, Tenover FC, [i#et al.#1i], eds. [i#Diagnostic Molecular Microbiology: Principles and Applications#1i]. MN, USA: Mayo Foundation, 1993; 553-9.
15. Kim J, Kwon Y, Pai H [i#et al.#1i] Survey of [i#Klebsiella pneumoniae#1i] strains producing extended-spectrum β-lactamases: Prevalence of SHV-12 and SHV-2a in Korea. [i#J Clin Microbiol#1i] 1998; [b#36#1b]: 1446-9.
16. Bonnet R, Dutour C, Sampaio JL [i#et al.#1i] Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240 → Gly. [i#Antimicrob Agents Chemother#1i] 2001; [b#45#1b]: 2269-75.
17. Poirel L, Le Thomas I, Naas T [i#et al.#1i] Biochemical sequence analyses of GES-1, a novel class A extended-spectrum β-lactamase, and the class 1 integron In52 from [i#Klebsiella pneumoniae. Antimicrob Agents Chemother#1i] 2000; [b#44#1b]: 622-32.
18. Vahaboglu H, Ozturk R, Akbal H [i#et al.#1i] Practical approach for detection and identification of OXA-10-derived ceftazidime-hydrolyzing extended-spectrum β-lactamases. [i#J Clin Microbiol#1i] 1998; [b#36#1b]: 827-9.
19. Thomson KS, Sanders CC. Detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae: Comparison of the double-disc and three-dimensional tests. [i#Antimicrob Agents Chemother#1i] 1992; [b#36#1b]: 1877-82.
20. Maslow JN, Slutsky AM, Arbeit RD, [i#et al.#1i] Application of pulsed-field gel electrophoresis to molecular epidemiology. In Persing DH, Smith TF, Tenover FC, [i#et al.#1i], eds. [i#Diagnostic Molecular Microbiology: Principles and Applications#1i]. MN, USA: Mayo Foundation, 1993; 563-72.
21. Jacoby G, Bush K. [i#Amino Acid Sequences for TEM, SHV, and OXA Extended-Spectrum and Inhibitor Resistant β-Lactamases#1i]. http://www.lahey.org/studies/webt.asp (14 January 2004, date last accessed).
22. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. [i#Antimicrob Agents Chemother#1i] 1995; [b#39#1b]: 1211-33.
23. Marumo K, Takeda A, Nakamura Y [i#et al.#1i] Detection of OXA-4 β-lactamase in [i#Pseudomonas aeruginosa#1i] isolates by genetic methods. [i#J Antimicrob Chemother#1i] 1999; [b#43#1b]: 187-93.
24. Danel F, Hall LM, Duke B [i#et al.#1i] OXA-17, a further extended-spectrum variant of OXA-10 β-lactamase, isolated from [i#Pseudomonas aeruginosa. Antimicrob Agents Chemother#1i] 1999; [b#43#1b]: 1362-6.
25. National Committee for Clinical Laboratory Standards. [i#Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fifth Edition: Approved Standard M7-A5#1i]. Wayne, PA, USA: NCCLS, 2000.
26. Vahaboglu H, Ozturk R, Aygun G [i#et al.#1i] Widespread detection of PER-1-type extended-spectrum β-lactamases among nosocomial [i#Acinetobacter#1i] and [i#Pseudomonas aeruginosa#1i] isolates in Turkey: A nationwide multicentre study. [i#Antimicrob Agents Chemother#1i] 1997; [b#41#1b]: 2265-9.
27. Yong D, Shin JH, Kim S [i#et al.#1i] High prevalence of PER-1 extended-spectrum β-lactamase-producing [i#Acinetobacter#1i] spp. in Korea. [i#Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 1749-51.
28. Sekowska A, Janicka G, KŁyszejko C [i#et al.#1i] Resistance of [i#Klebsiella pneumoniae#1i] strains producing and not producing ESBL (extended-spectrum beta-lactamase) type enzymes to selected non-beta-lactam antibiotics. [i#Med Sci Monit#1i] 2002; [b#8#1b]: 100-4.
29. Procop GW, Tuohy MJ, Wilson DA [i#et al.#1i] Cross-class resistance to non-β-lactam antimicrobials in extended-spectrum β-lactamase-producing [i#Klebsiella pneumoniae. Am J Clin Pathol#1i] 2003; [b#120#1b]: 265-7.
30. Leotard S, Poirel L, Leblanc PE [i#et al.#1i] In vivo selection of oxacillinase-mediated ceftazidime resistance in [i#Pseudomonas aeruginosa. Microb Drug Resist#1i] 2001; [b#7#1b]: 273-5.
31. Muniesa M, Garciá A, Miró E [i#et al.#1i] Bacteriophages and diffusion of β-lactamase genes. [i#Emerg Infect Dis#1i] 2004; [b#10#1b]: 1134-7.
32. Hendrix RW, Smith MC, Burns RN [i#et al.#1i] Evolutionary relationships among diverse bacteriophages and prophages: All the world's a phage. [i#Proc Natl Acad Sci USA#1i] 1999; [b#96#1b]: 2192-7.